Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000)

PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) is a global surveillance study established in 1999 to monitor antibacterial resistance of respiratory tract organisms. Thirteen centers from Argentina, Brazil and Mexico participat ed during 1999-2000;...

Full description

Bibliographic Details
Main Authors: C. Mendes, M. E. Marin, F. Quiñones, J. Sifuentes-Osornio, C. Cuilty Siller, M. Castanheira, C. M. Zoccoli, H. López, A. Súcari, F. Rossi, G. Barriga Angulo, A.J.A. Segura, C. Starling, I. Mimica, D. Felmingham
Format: Article
Language:English
Published: Elsevier
Series:Brazilian Journal of Infectious Diseases
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000100006&lng=en&tlng=en
id doaj-f59c18588e334a6a92b8b3717341e87f
record_format Article
spelling doaj-f59c18588e334a6a92b8b3717341e87f2020-11-25T02:58:17ZengElsevierBrazilian Journal of Infectious Diseases1678-439171446110.1590/S1413-86702003000100006S1413-86702003000100006Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000)C. Mendes0M. E. Marin1F. Quiñones2J. Sifuentes-Osornio3C. Cuilty Siller4M. Castanheira5C. M. Zoccoli6H. López7A. Súcari8F. Rossi9G. Barriga Angulo10A.J.A. SeguraC. Starling11I. Mimica12D. Felmingham13Fleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicineFleury Centre of Diagnostic MedicinePROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) is a global surveillance study established in 1999 to monitor antibacterial resistance of respiratory tract organisms. Thirteen centers from Argentina, Brazil and Mexico participat ed during 1999-2000; they collected 1,806 isolates (Streptococcus pneumoniae 518, Haemophilus influenzae 520, Moraxella catarrhalis 140, Staphylococcus aureus 351, S. pyogenes 277). Overall, 218 (42.1%) of the S. pneumoniae isolates had reduced susceptibility to penicillin, 79 (15.3%) were penicillin-resistant and 79 (15.3%) were erythromycin-resistant. Mexico had the highest prevalence of penicillin (76.5%) and erythromycin (31.2%) resistance. Of 77 erythromycin-resistant S. pneumoniae tested for resistance genotype, 43 possessed mef(A), 33 possessed erm(B) and 1 possessed both erm(B) and mef(A) mechanism. All S. pneumoniae isolates were fully susceptible to telithromycin, linezolid, teicoplanin and vancomycin. Among H. influenzae isolates, 88 (16.9%) produced b-lactamase, ranging from 11% (Brazil) to 24.5% (Mexico). Among M. catarrhalis isolates, 138 (98.6%) produced b-lactamase. Twenty-four (8.7%) of the S. pyogenes isolates were erythromycin-resistant; resistance being attributable to mefA (n=18), ermTR (n=5) and ermB (n=1). All H. influenzae, M. catarrhalis and S. pyogenes were fully susceptible to telithromycin. Methicillin resistance was found in 26.5% of the S. aureus isolates (Argentina 15%; Mexico 20%; Brazil 31.3%). Telithromycin was effective against 97.7% of methicillin-susceptible isolates. PROTEKT confirms that antibacterial resistance is an emerging problem in Latin America. The previously reported high levels of pneumococcal resistance to the b-lactam and macrolides were exceeded. New agents that do not induce resistance or that exert low selective pressure, e.g. telithromycin, are essential to safeguard future antibacterial efficacy.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000100006&lng=en&tlng=enPROTEKTLatin Americaresistancerespiratory tract infectionsStreptococcus pneumoniaeHaemophilus influenzaeMoraxella catarrhalisStreptococcus pyogenesStaphylococcus aureus
collection DOAJ
language English
format Article
sources DOAJ
author C. Mendes
M. E. Marin
F. Quiñones
J. Sifuentes-Osornio
C. Cuilty Siller
M. Castanheira
C. M. Zoccoli
H. López
A. Súcari
F. Rossi
G. Barriga Angulo
A.J.A. Segura
C. Starling
I. Mimica
D. Felmingham
spellingShingle C. Mendes
M. E. Marin
F. Quiñones
J. Sifuentes-Osornio
C. Cuilty Siller
M. Castanheira
C. M. Zoccoli
H. López
A. Súcari
F. Rossi
G. Barriga Angulo
A.J.A. Segura
C. Starling
I. Mimica
D. Felmingham
Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000)
Brazilian Journal of Infectious Diseases
PROTEKT
Latin America
resistance
respiratory tract infections
Streptococcus pneumoniae
Haemophilus influenzae
Moraxella catarrhalis
Streptococcus pyogenes
Staphylococcus aureus
author_facet C. Mendes
M. E. Marin
F. Quiñones
J. Sifuentes-Osornio
C. Cuilty Siller
M. Castanheira
C. M. Zoccoli
H. López
A. Súcari
F. Rossi
G. Barriga Angulo
A.J.A. Segura
C. Starling
I. Mimica
D. Felmingham
author_sort C. Mendes
title Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000)
title_short Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000)
title_full Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000)
title_fullStr Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000)
title_full_unstemmed Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000)
title_sort antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in latin america: results from the protekt surveillance study (1999-2000)
publisher Elsevier
series Brazilian Journal of Infectious Diseases
issn 1678-4391
description PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) is a global surveillance study established in 1999 to monitor antibacterial resistance of respiratory tract organisms. Thirteen centers from Argentina, Brazil and Mexico participat ed during 1999-2000; they collected 1,806 isolates (Streptococcus pneumoniae 518, Haemophilus influenzae 520, Moraxella catarrhalis 140, Staphylococcus aureus 351, S. pyogenes 277). Overall, 218 (42.1%) of the S. pneumoniae isolates had reduced susceptibility to penicillin, 79 (15.3%) were penicillin-resistant and 79 (15.3%) were erythromycin-resistant. Mexico had the highest prevalence of penicillin (76.5%) and erythromycin (31.2%) resistance. Of 77 erythromycin-resistant S. pneumoniae tested for resistance genotype, 43 possessed mef(A), 33 possessed erm(B) and 1 possessed both erm(B) and mef(A) mechanism. All S. pneumoniae isolates were fully susceptible to telithromycin, linezolid, teicoplanin and vancomycin. Among H. influenzae isolates, 88 (16.9%) produced b-lactamase, ranging from 11% (Brazil) to 24.5% (Mexico). Among M. catarrhalis isolates, 138 (98.6%) produced b-lactamase. Twenty-four (8.7%) of the S. pyogenes isolates were erythromycin-resistant; resistance being attributable to mefA (n=18), ermTR (n=5) and ermB (n=1). All H. influenzae, M. catarrhalis and S. pyogenes were fully susceptible to telithromycin. Methicillin resistance was found in 26.5% of the S. aureus isolates (Argentina 15%; Mexico 20%; Brazil 31.3%). Telithromycin was effective against 97.7% of methicillin-susceptible isolates. PROTEKT confirms that antibacterial resistance is an emerging problem in Latin America. The previously reported high levels of pneumococcal resistance to the b-lactam and macrolides were exceeded. New agents that do not induce resistance or that exert low selective pressure, e.g. telithromycin, are essential to safeguard future antibacterial efficacy.
topic PROTEKT
Latin America
resistance
respiratory tract infections
Streptococcus pneumoniae
Haemophilus influenzae
Moraxella catarrhalis
Streptococcus pyogenes
Staphylococcus aureus
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000100006&lng=en&tlng=en
work_keys_str_mv AT cmendes antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
AT memarin antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
AT fquinones antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
AT jsifuentesosornio antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
AT ccuiltysiller antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
AT mcastanheira antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
AT cmzoccoli antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
AT hlopez antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
AT asucari antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
AT frossi antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
AT gbarrigaangulo antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
AT ajasegura antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
AT cstarling antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
AT imimica antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
AT dfelmingham antibacterialresistanceofcommunityacquiredrespiratorytractpathogensrecoveredfrompatientsinlatinamericaresultsfromtheprotektsurveillancestudy19992000
_version_ 1724707365817679872